6 years (range 19–78 years), 63% were male and 37% were HBeAg positive at baseline. Responses to treatment in both groups are shown in Table 1. Table 1: Responses to entecavir in patients with cirrhosis and without cirrhosis No Cirrhosis (n = 70) Cirrhosis
(n = 30) p value BASELINE Age, years 45.7 ± 13.2 48.8 ± 14.6 Ixazomib supplier 0.3029 Gender, M : F 40:30 23:7 0.0740 Positive HBeAg, n (%) 25 (36) 12 (40) 0.8215 Viral load, log10 IU/ml 5.30 ± 2.08 5.49 ± 1.84 0.6976 ALT, U/L 119 149 0.7528 eGFR, mL/min/1.73 m∧2 95.98 94.88 0.8307 AT 12 MONTHS Viral load, mean log10 IU/ml 2.03 ± 0.71 2.03 ± 1.25 0.9791 2 log drop from baseline, n/total (%) 36/36 (100) 13/14 (93) 0.2800 Viral load <1.73 log10 IU/ml, n/total (%) 35/51 (69) 13/23 (59) 0.4305 ALT < 35 U/L, n (%) 20/38 (53) 8/24 (33) 0.1915 HBe-Ag seroconversion, n (%) 5/25 (20) 1/12 (8.3) 0.6409 eGFR, mL/min/1.73 m∧2 92.58 88.70 0.5653 Conclusions: Entecavir 0.5 mg daily is an effective treatment in
patients with and without cirrhosis with 98% achieving 2 log10 reduction in viral load and 65% achieving viral load to below limit of quantification after 12 months. There were no significant differences in virological Selleckchem 3 Methyladenine and biochemical responses to treatment in both groups. Although HBeAg seroconversion is slightly higher in the group without cirrhosis, the difference was not significant. There was no change in renal function after 12 months treatment with entecavir. ZY NG,1 J KONG,1 N KONTORINIS,1 L TARQUINIO,1 J FLEXMAN,2 W CHENG1 Depts of 1Gastroenterology & Hepatology and 2Microbiology, Royal Perth Hospital, Perth Western Australia Background and Aims: Virological suppression and HBeAg seroconversion are important objectives in the treatment of chronic hepatitis B (CHB) patients. HBeAg seroconversion may enable finite treatment with oral nucleos(t)ide analogues. Duration of therapy in these patients may be influenced by the time for HBeAg seroconversion. The aims of the study are (1) To assess
factors predicting virological suppression in CHB patients after treatment with entecavir for 12 months (2) To determine association 上海皓元 between virological suppression and HBeAg seroconversion. Methods: Retrospective study of all CHB patients treated with entecavir 0.5 mg at Royal Perth Hospital between 2007 and 2012. Subjects were identified using pharmacy database for entecavir scripts and data was obtained from electronic database. Data collected included demographics, stage of liver disease, HBeAg status, viral load, ALT and GGT at baseline and during treatment. Virological suppression was defined as suppressed hepatitis B viral load (VL) to < log101.73 IU/ml (lower limit of quantification). T-test was used to compare means and Fischer’s exact test was used to compare between groups with statistical significance determined at p < 0.05. Results: 100 CHB patients were included in the study. Mean age was 46.6 yrs (range 19–78 yrs) with mean length of treatment of 22.8 months.